CORONA Remedies Board to Consider Q2 and H1 Results on 30th Oct'26
Corona Remedies Ltd 路 Intimation 路 30 Oct 2026, 5:30 am
CORONA Remedies Board to Consider Q2 and H1 Results on 30th Oct'26 CORONA Remedies Limited has scheduled a Board of Directors meeting on 30th Oct'26 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26. Additionally, the trading window for dealing in company securities remains closed until 1st Nov'26 pursuant to insider trading regulations.
Original exchange filing (PDF)
More announcements from Corona Remedies Ltd
- Intimation of Participation in Analyst / Investor Conference 路 16 Nov 2026
- Intimation of Participation in Analyst / Investor Conference 路 07 Nov 2026
- Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the second quarter and half year ended September 30, 2026 路 05 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 04 Nov 2026
- Audio Recording of Q2H1FY27 Earnings Conference Call with Analysts / Investors 路 02 Nov 2026
- Intimation for Analyst / Investor Meet 路 31 Oct 2026
- Analyst / Investor Presentation 路 31 Oct 2026
- Press Release on Financial Results for second quarter and half year ended on September 30, 2026 路 31 Oct 2026
